தலை மற்றும் கழுத்து புற்றுநோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தலை மற்றும் கழுத்து புற்றுநோய். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தலை மற்றும் கழுத்து புற்றுநோய் Today - Breaking & Trending Today

"Collaborative, interprofessional nutritional care within head and neck" by Emily Hazzard, Karen Walton et al.

Evidence-based guidelines (EBGs) for patients with head and neck cancer (HNC) recommend that nutritional care is delivered by an interprofessional team inclusive of dietitians, doctors, nurses, and speech pathologists. Barriers to collaboration exist within interprofessional teams. However, research on this is currently lacking in the HNC setting, particularly with regard to the provision of nutritional care. This study aimed to explore what facilitates collaborative nutritional care for patients with HNC from the perspectives of different healthcare professionals. This qualitative study used a grounded theory approach. Healthcare professionals from two radiotherapy departments in the United States and two in Australia were interviewed. Forty-six interviews were completed with 17 radiation-oncologists, 12 nurses, eleven dietitians, and 6 speech-pathologists. Collaborative nutritional care for patients with HNC was underpinned by three categories and six sub-categories: access to dietit ....

United States , Head And Neck Cancer , Interprofessional Collaboration , Multidisciplinary Team , Qualitative Research , ஒன்றுபட்டது மாநிலங்களில் , தலை மற்றும் கழுத்து புற்றுநோய் ,

Germany's Merck Inks €900M Agreement For Head And Neck Cancer Drug

Germany's Merck Inks €900M Agreement For Head And Neck Cancer Drug
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Merck Kgaa , Head And Neck Cancer , Squamous Cell Carcinoma , Merck Stock , Licensing Agreement , Clinical Development , தலை மற்றும் கழுத்து புற்றுநோய் , மெர்க் ஸ்டாக் , மருத்துவ வளர்ச்சி ,

Merck agrees $1 billion deal with Debiopharm for head and neck cancer drug

Germany's Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to develop and commercialise Xevinapant for head and neck cancer. Under the terms of the licensing deal, Merck will pay Debiopharm 188 million euros upfront and has agreed to further regulatory and commercial milestones worth up to 710 million euros, as well as royalties. "This late-stage asset complements our Healthcare pipeline, which will be one of Merck's key growth drivers in the coming years," Chief Executive Stefan Oschmann said in a statement. ....

Head And Neck Cancer , Stefan Oschmann , தலை மற்றும் கழுத்து புற்றுநோய் ,